Efficacy evaluation of prime-boost protocol: Canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats

AIDS

Volumn 12, Issue 1, 1998, Pages 11-18

  Tellier, Marinka C ^a   Pu, Ruiyu ^a   Pollock, David ^a   Vitsky, Allison ^a   Tartaglia, James ^b   Paoletti, Enzo ^b   Yamamoto, Janet K ^a,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b Virogenetics Corporation   (United States)

^c Department of Pathobiology ^*  (United States)

Author keywords

Canarypoxvirus based recombinant vaccine; Cytotoxic T lymphocyte; Feline immunodeficiency virus; T helper; Vaccine; Virus neutralising antibodies

Indexed keywords

INACTIVATED VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT; CONTROLLED STUDY; EMBRYO; FELINE IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; RETROVIRUS INFECTION; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; AVIPOXVIRUS; BONE MARROW CELLS; CATS; CROSS REACTIONS; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; GENE PRODUCTS, GAG; IMMUNODEFICIENCY VIRUS, FELINE; LEUKOCYTES, MONONUCLEAR; LYMPH NODES; NEUTRALIZATION TESTS; PILOT PROJECTS; POLYMERASE CHAIN REACTION; RNA-DIRECTED DNA POLYMERASE; SPECIFIC PATHOGEN-FREE ORGANISMS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 0031962046     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199801000-00002     Document Type: Article

References (32)

1. Cheingsong-Popov R, Chappey C, Callow D, Lister S, Bobkov A, Weher J: HIV-1 V3-scrolypcs: distribution and correlation with genotypes. X International Conference on AIDS. Yokohama, August 1994 [abstract PC0430].
2. Broclinc SK, Mascola JR, Weiss PJ, et al.: Detection of diverse HIV-1 genetic subtypes in the USA. Lancet 1995, 346:1198-1199.
3. Pedersen NC, Ho E, Brown L, Yamamoto JK: Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987, 235:790-793.
4. Yamamoto JK, Sparger E, Ho EW, et al.: Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am J Vet Res 1988, 49:1246-1258.
5. Kakinuma S, Motokawa K, Hohdatsu T, Yamamoto JK, Koyoma H, Hashimoto H: Nucleotide sequence of feline immunodeficiency virus: classification of Japanese isolates into two subtypes which are distinct from non-Japanese subtypes. J Virol 1995, 69:3639-3646.
6. Rigby MA, Holmes EC, Pistcllo M, Mackay A, Brown AJ, Neil JC: Evolution of structural proteins of feline immunodeficiency virus: molecular epidemiology and evidence of selection for change. J Gen Virol 1993, 74:425-436.
7. Sodora DL, Shpaer EG, Kitchell BE, Dow SW, Hoover EA, Mullins JI: Identification of three feline immunodeficiency virus (FIV) env gene subtypes and comparison of the FIV and human immunodeficiency virus type 1 evolutionary patterns. J Virol 1994, 68:2230-2238.
8. Yamamoto JK, Okuda T, Ackley CD, et al.: Experimental vaccine protection against feline immunodeficiency virus. AIDS Res Hum Retroviruses 1991, 7:911-922.
9. Verschoor EJ, Van Vliet AL, Egberink HF, et al.: Vaccination against feline immunodeficiency virus using fixed infected cells. Vet Immunol Immunopathol 1995, 46:139-149.
10. Yamamoto JK, Hohdatshu T, Olmstead RA, et al.: Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J Virol 1993, 67:601-605.
11. Johnson CM, Torres BA, Koyama H, Yamamoto IK: FIV as model for AIDS. AIDS Res Hum Ketroviruses 1994, 10:225-228.
12. Stolt EJ: Anti-cell antibody in macaques. Nature 1991, 353:393.
13. Cranage MP, Polyanskaya N, McBride B, et al.: Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retroviruses 1993, 9:13-22.
14. Hosie MJ, Osborne R, Yamamoto JK, Neil J, larrett O: Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines. J Virol 1995, 69:1253-1255.
15. Girard M, Meignier B, Barre-Sinoussi F, et al.: Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol 1995, 69:6239-6248.
16. Perkus ME, Tarlaglia J, Pooletti E, et al.: Poxvirus based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol 1995, 58:1-13.
17. Baxby D, Paoletti E: Potential use of non-replicating vectors as recombinant vaccines. Vaccine 1992, 10:8-9.
18. Tartaglia J, Jarrett O, Neil JC, et al.: Protection of cats against feline leukemia virus by vaccination with canarypox virus recombinant, ALVAC-FL. J Virol 1993, 67:2370-2375.
19. Franchini G, Tarlaglia J, Markham P, et al.: Highly attenuated HTLV-I env poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits. AIDS Res Hum Retroviruses 1995, 11:307-313.
20. Francini G, Guroff MR, Tarlaglia J, et al.: Highly attenuated HIV-2 recombinant poxviruses, but not HIV-2 rccombinant salmonella vaccines, induce long lasting protection in rhesus macaques. AIDS Res Hum Retroviruses 1995, 11:909-920.
21. Abimiku A, Franchini G, Tartaglia J, el al.: HIV-1 rccombinant poxvirus vaccine induces cross-protection in rhesus macaques. Nature Med 1995, 1:321-329.
22. Girard M, Barre-Sinoussi F, Tartaglia J, et al.: Immunization with an HIV-1 canarypox virus recombinant confers protection against genital HIV-1 challenge in chimpanzees. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA393].
23. Van der Ryst E, Fultz PN, Tartaglia J, et al.: Protection from HIV-1 challenge in chimpanzees by immunization with an canarypoxvirus recombinanl. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeA280].
24. Sons W, Collison EW, Bilingslcy P, Brown WC: Induction of feline immunodeficiency virus specific cytolytic T-cell responses from experimentally infected cats. J Virol 1992, 66:5409-5-417.
25. Okada S, Pu R, Young E, Stoffs WV, Yamamoto JK: Superinfection of cats with feline immunodeficiency virus subtypes A and B. AIDS Res Hum Retroviruses 1994, 10:1739-1746.
26. Pialoux G, Excler JL, Riviere Y, et al.: A prime-boost approach to HIV preventive vaccine using a recombinant canarypoxvirus expressing glycoprolein 160(MN) followed by a rccombinant glycoprotein 160 (MN/LAI). AIDS Res Hum Retroviruses 1995, 11:373-381.
27. Clements ML, Weinhold K, Siliciano R, et al.: HIV immunity induced by canarypox (ALVAC)-MN gp160, -SF-2, rgp120 or both. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA281].
28. Lawrence C, Weinholel K, McElrath J, et al.: Safety and immunogenicity of live recombinant canarypox vector containing the envelope, gag and protease genes of HIV-1 seronegative adult volunteers. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoA282].
29. MNenv gene. J Infect Dis 1995, 171:1623-1627.
30. Hosie MJ, Flynn N: FIV vaccination: characterization of the immune correlates of protection. J Virol 1996, 70:7561-7568.
31. Clements JE, Montelaro RC, Zink C, et al.: Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage tropic simian immunodeficiency virus. J Virol 1995, 69:2737-2744.
32. Tellier MC, Soos J, Pu, Pollock D, Yamamoto JK: Development of FIV-specific cytolytic T-lymphocyte responses in cats upon immunisation with FIV vaccines. Vet Microbiol 1997, 57:1-11.